Hope rises for cancer treatment as key drug gets U.S. approval

Drugs used to illustrate the story.
Drugs used to illustrate the story.

The U.S. Food and Drug Administration (FDA) on Wednesday granted breakthrough therapy designation to drug maker, AstraZeneca’s biggest new drug hope Durvalumab for the treatment in bladder cancer.

The experimental medicine is a “PD-L1’’ therapy that fights cancer by boosting the immune system.

The breakthrough therapy designation expedites the development and review of medicines intended to treat serious or life-threatening diseases.

The drug, Durvalumab, is also being developed as a treatment for lung, head and neck, gastric, pancreatic, liver and blood cancers.

The drug is competing with rival products made by Bristol-Myers Squibb, Merck and Roche.



Now available on

  Premium Times Android mobile applicationPremium Times iOS mobile applicationPremium Times blackberry mobile applicationPremium Times windows mobile application

TEXT AD: To place a text-based advert here. Call Willie - +2347088095401

All rights reserved. This material and any other material on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from PREMIUM TIMES.